Corcept Therapeutics Inc. (CORT) Valuation
Historical valuation analysis based on 500 data points (2024-09-24 to 2026-09-22)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders...
Corcept Therapeutics Inc. (CORT) currently trades at a P/E ratio of 259.20 (historical range: 35.13–272.58, median: 64.15), placing it at the 98th percentile — expensive relative to its history, P/S ratio of 15.96 (range: 5.20–19.97, 98th percentile — expensive relative to its history).
Over the historical period (2024-09-24 to 2026-09-22), Corcept Therapeutics Inc.'s P/E ratio has expanded by 126% over the observed period (from an average of 54.3 to 122.5).
Corcept Therapeutics Inc. trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 259.20 | 35.13 | 64.15 | 272.58 | 98th | expensive relative to its history |
| P/S Ratio | 15.96 | 5.20 | 11.58 | 19.97 | 98th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.02 | 0.04 | 2th | expensive relative to its history |
Corcept Therapeutics Inc. (CORT) Valuation & P/E History
Corcept Therapeutics Inc. (CORT) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $117.50 with a market capitalization of $12.7 billion. This page provides historical valuation analysis for CORT based on 500 data points covering 2024-09-24 to 2026-09-22. The P/E ratio of 259.20 is above the historical median of 64.15, placing CORT at the 98th percentile of its valuation range. The P/S ratio of 15.96 compares to a median of 11.58.
CORT Valuation Metrics & Historical Range
The valuation table above shows Corcept Therapeutics Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether CORT is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests CORT is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Corcept Therapeutics Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is CORT Overvalued or Undervalued?
Corcept Therapeutics Inc. trades well above its own historical valuation range across most metrics. The overall valuation percentile of 98 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive CORT is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full CORT analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.CORT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.